Biomea Fusion reports Phase 1 weight‑loss data for oral GLP‑1 candidate BMF‑650

Biomea Fusion disclosed results of its Phase 1 GLP‑131 trial of BMF‑650, an oral small‑molecule GLP‑1 agonist. In outpatient cohorts 1‑4, mean weight loss at Day 29 ranged from 1.5 % to 3.2 % versus 0.1 % for pooled placebo. A confined fifth cohort achieved a mean loss of 6.1 % (about 6.2 kg) after a rapid titration to 400 mg daily. No severe or serious adverse events were reported, and the company announced a conference call to discuss the data.

The company said the data support pursuing a strategic partnership or licensing deal for later‑stage development. Investors may view the early efficacy and tolerability as a catalyst for future financing or partnership activity.

  • 1Mean weight reduction in Cohorts 1‑4 at Day 29 ranged from 1.5 % to 3.2 %.
  • 2Pooled placebo participants lost 0.1 % of body weight at Day 29.
  • 3The confined Cohort 5 showed a mean weight loss of 6.1 % (approximately 6.2 kg) at Day 29.
  • 4All treatment‑emergent adverse events across the five active‑dose cohorts were mild or moderate; no severe or serious events occurred.
  • 5The company will hold a conference call on October 13, 2026, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time).

Sources